Literature DB >> 24903343

Progression of diffuse myocardial fibrosis assessed by cardiac magnetic resonance T₁ mapping.

Colin J Yi1, Eunice Yang, Shenghan Lai, Neville Gai, Chia Liu, Songtao Liu, Stefan L Zimmerman, João A C Lima, David A Bluemke.   

Abstract

To evaluate long-term changes in diffuse myocardial fibrosis using cardiac magnetic resonance (CMR) with late gadolinium enhancement (LGE) and T1 mapping. Patients with chronic stable cardiomyopathy and stable clinical status (n = 52) underwent repeat CMR at a 6 month or greater follow up interval and had LGE and left ventricular (LV) T1 mapping CMR. Diffuse myocardial fibrosis (excluding areas of focal myocardial scar) was assessed by post gadolinium myocardial T1 times. Mean baseline age of 52 patients (66 % male) was 35 ± 19 years with a mean interval between CMR examinations of 2.0 ± 0.8 years. CMR parameters, including LV mass and ejection fraction, showed no change at follow-up CMR (p > 0.05). LVT1 times (excluding focal scar) decreased over the study interval (from 468 ± 106 to 434 ± 82 ms, p = 0.049). 38 Patients had no visual LGE-, while 14 were LGE+. For LGE- patients, greater change in LV mass and end systolic volume index were associated with change in T1 time (β = -2.03 ms/g/m(2), p = 0.035 and β = 2.1 ms/mL/m(2), p = 0.029, respectively). For LGE+ patients, scar size was stable between CMR1 and CMR2 (10.7 ± 13.8 and 11.5 ± 13.9 g, respectively, p = 0.32). These results suggest that diffuse myocardial fibrosis, as assessed by T1 mapping, progresses over time in patients with chronic stable cardiomyopathy.

Entities:  

Mesh:

Year:  2014        PMID: 24903343      PMCID: PMC4169726          DOI: 10.1007/s10554-014-0459-z

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  35 in total

1.  Molecular imaging: magnetic resonance angiography in pulmonary embolism diagnosis.

Authors:  Joana Osório
Journal:  Nat Rev Cardiol       Date:  2010-06       Impact factor: 32.419

2.  Hypertrophic cardiomyopathy complicated by large apical aneurysm and thrombus, presenting as ventricular tachycardia.

Authors:  Cameron J Holloway; Timothy R Betts; Stefan Neubauer; Saul G Myerson
Journal:  J Am Coll Cardiol       Date:  2010-11-30       Impact factor: 24.094

3.  Myocardial T1 mapping with MRI: comparison of look-locker and MOLLI sequences.

Authors:  Marcelo Souto Nacif; Evrim B Turkbey; Neville Gai; Saman Nazarian; Rob J van der Geest; Radwa A Noureldin; Christopher T Sibley; Martin Ugander; Songtao Liu; Andrew E Arai; João A C Lima; David A Bluemke
Journal:  J Magn Reson Imaging       Date:  2011-09-23       Impact factor: 4.813

4.  Acute left ventricular remodeling following myocardial infarction: coupling of regional healing with remote extracellular matrix expansion.

Authors:  William Chan; Stephen J Duffy; David A White; Xiao-Ming Gao; Xiao-Jun Du; Andris H Ellims; Anthony M Dart; Andrew J Taylor
Journal:  JACC Cardiovasc Imaging       Date:  2012-09

5.  Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death.

Authors:  Leah Iles; Heinz Pfluger; Lisa Lefkovits; Michelle J Butler; Peter M Kistler; David M Kaye; Andrew J Taylor
Journal:  J Am Coll Cardiol       Date:  2011-02-15       Impact factor: 24.094

6.  Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients.

Authors:  B López; R Querejeta; N Varo; A González; M Larman; J L Martínez Ubago; J Díez
Journal:  Circulation       Date:  2001-07-17       Impact factor: 29.690

7.  T1 mapping of the gadolinium-enhanced myocardium: adjustment for factors affecting interpatient comparison.

Authors:  Neville Gai; Evrim B Turkbey; Saman Nazarian; Rob J van der Geest; Chia-Ying Liu; João A C Lima; David A Bluemke
Journal:  Magn Reson Med       Date:  2010-12-16       Impact factor: 4.668

8.  Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus.

Authors:  Valentina O Puntmann; David D'Cruz; Zachary Smith; Ana Pastor; Peng Choong; Tobias Voigt; Gerry Carr-White; Shirish Sangle; Tobias Schaeffter; Eike Nagel
Journal:  Circ Cardiovasc Imaging       Date:  2013-02-12       Impact factor: 7.792

9.  Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study.

Authors:  Andrew S Flett; Daniel M Sado; Giovanni Quarta; Mariana Mirabel; Denis Pellerin; Anna S Herrey; Derek J Hausenloy; Cono Ariti; John Yap; Shyam Kolvekar; Andrew M Taylor; James C Moon
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2012-05-25       Impact factor: 6.875

10.  Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy.

Authors:  Valentina O Puntmann; Tobias Voigt; Zhong Chen; Manuel Mayr; Rashed Karim; Kawal Rhode; Ana Pastor; Gerald Carr-White; Reza Razavi; Tobias Schaeffter; Eike Nagel
Journal:  JACC Cardiovasc Imaging       Date:  2013-03-14
View more
  3 in total

Review 1.  Cardiovascular imaging 2014 in the International Journal of Cardiovascular Imaging.

Authors: 
Journal:  Int J Cardiovasc Imaging       Date:  2015-03       Impact factor: 2.357

2.  Prognostic value of T1 mapping and extracellular volume fraction in cardiovascular disease: a systematic review and meta-analysis.

Authors:  Baiyan Zhuang; Arlene Sirajuddin; Shuli Wang; Andrew Arai; Shihua Zhao; Minjie Lu
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

3.  Prospective cardiovascular magnetic resonance imaging in adults with Alström syndrome: silent progression of diffuse interstitial fibrosis.

Authors:  Shanat Baig; Rory Dowd; Nicola C Edwards; James Hodson; Larissa Fabritz; Ravi Vijapurapu; Boyang Liu; Tarekegn Geberhiwot; Richard P Steeds
Journal:  Orphanet J Rare Dis       Date:  2020-06-05       Impact factor: 4.123

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.